According to the Alzheimer’s Association, nearly 7 million Americans are living with Alzheimer's disease in 2024, and this number is projected to rise to nearly 13 million by 2050. Clarity, a pioneering neurotechnology company focused on delaying Alzheimer’s, today announced the appointment of Brad Barrish as Chief Operating Officer (COO) and Co-Founder. Bringing a wealth of experience from leading consumer hardware companies, Brad will play a crucial role in driving Clarity’s mission to extend the healthspan of individuals affected by neurodegenerative diseases through groundbreaking technology and experiences for patients and caregivers. Brad will oversee organizational design, people, and product development.

“Clarity’s mission is what brought us together. So many people need access to better healthcare solutions in neurology, and Brad is a visionary leader with a personal connection. He understands what it is like to be a caregiver for someone with a neurological condition and has seen the patient experience first-hand, bringing an extremely valuable perspective to the team,” said Raphael Certain, Co-founder and CEO of Clarity. “Additionally, Brad's strong background in product, consumer experience, and go-to-market strategy will be instrumental as we push the boundaries of science to defeat neurodegenerative diseases.”

Brad Barrish was most recently Vice President of Customer Experience at Oura, a leader in the health wearables industry. Prior to that, he served as Director of Customer Experience at Sonos, the world’s leading sound experience company. For the last several years, he has been a respected and sought-after mentor with Techstars, a leading pre-seed investor and accelerator, where he worked closely with founders and founding teams to deliver exceptional consumer products across music and health programs.

In addition to decades of experience with technology startups and widely recognized consumer brands, Brad has also directly experienced the immense challenge of caring for family members suffering from neurodegenerative diseases. His grandfather died from complications related to Alzheimer’s, and his mother has Parkinson’s and Lewy body dementia. His commitment to improving the lives of those suffering from neurodegenerative diseases and those who care for them is personal.

“Having been directly impacted by neurodegenerative diseases in my family, joining Clarity and dedicating so much of my time and energy to helping the many people impacted by these awful diseases feels like a natural decision,” said Brad Barrish, Co-founder and COO of Clarity. “Working alongside an endlessly determined founder like Raphael and a brilliant, dedicated team to develop a potentially life-changing therapy is an incredible opportunity. I’m excited to apply everything I’ve learned in my career thus far to make Clarity a successful pioneer in neurotechnology.”

Clarity’s mission is to extend the healthspan of all individuals by enhancing quality of life through innovative health solutions. The company is developing a first-of-its-kind therapy that combines immersive auditory and visual stimulation with biosensors to slow the progression of Alzheimer’s and other neurodegenerative diseases. This home-based platform will provide personalized treatment and monitoring, establishing a new category in healthcare.

In the last 12 months, Clarity has achieved significant milestones, including receiving support from industry pioneers from the University of California, San Francisco's Neuroscape lab. Clarity has also sold prototypes to prestigious institutions like Oxford University and established more than six research and clinical collaborations. Clarity also added renowned neurologist Dr. Pablo Villoslada to its medical advisory board, which also includes UCSF’s Dr. Theodore Zanto, University of Glasgow’s Dr. Simon Hanslmayr and University of Nottingham’s Dr. Andrew Clouter.

Clarity is on track to complete its Phase 1 Alzheimer’s clinical trial and has received support from notable investors, including Bayer’s former CIO, Pareto Holdings, Orrick Herrington & Sutcliffe, and Andreessen Horowitz’s Scout Fund. In the second half of 2024, the company will focus on new key hires and technology development, with plans to launch longitudinal tolerability and early efficacy clinical trials in 2025.

About Clarity

Clarity is a trailblazing company dedicated to defeating neurodegenerative diseases through innovative health solutions. By delivering a unique neuromodulation therapy that combines immersive sensory stimulation with cutting-edge biosensors, Clarity aims to improve the lives of individuals with neurodegenerative diseases like Alzheimer’s, Multiple Sclerosis and Parkinson’s. The company’s mission is to create a home-based, personalized treatment and monitoring platform, revolutionizing how brain health is managed and maintained. For more information, visit: https://clarity-technologies.com/

Clarity is looking to expand its partnerships. If you're part of a pharmaceutical company, research institution, or an investor interested in collaborating, feel free to contact our founders.

For more information, please contact: contact@clarity-technologies.com